This story is currently available in английский only — a translation isn't ready yet.
Critical Medicines Act passes key milestone as patient groups welcome orphan drug protections within new framework.
ℹ️ Озвучка браузером · студийный голос ИИ скоро
EU legislation strengthening medicine supply chains has reached an important milestone, with patient organisations welcoming the inclusion of orphan medicinal products within the scope of the new framework. The Critical Medicines Act aims to reduce European dependency on external suppliers for essential medications. Patient groups praised protections for rare disease treatments, though industry representatives expressed concerns about competitiveness requirements. The legislation represents the EU's strategy to secure pharmaceutical supply chains following pandemic-related shortages.
The EU's Critical Medicines Act has advanced through legislation to reduce reliance on external pharmaceutical suppliers, with new protections for orphan drugs treating rare diseases. Patient groups support the framework, though pharmaceutical companies worry about added competitiveness requirements.
Medicine prices and availability in your country may stabilize as the EU builds domestic production capacity, reducing future shortages. If you or family members depend on rare disease treatments, new supply chain protections could mean more reliable access to medications.